Intellia Therapeutics, Inc. (NTLA)
Company Info
ISIN | US45826J1051 |
---|---|
CUSIP | 45826J105 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $2.65B |
---|---|
EPS | -$5.34 |
Revenue (TTM) | $51.77M |
Gross Profit (TTM) | -$367.86M |
EBITDA (TTM) | -$476.94M |
Year Range | $22.67 - $47.48 |
Target Price | $76.00 |
Short % | 11.96% |
Short Ratio | 5.74 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Popular comparisons: NTLA vs. CRSP, NTLA vs. SCHD, NTLA vs. AAPL, NTLA vs. GOOGL
Return
Intellia Therapeutics, Inc. had a return of -11.61% year-to-date (YTD) and -32.66% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -11.61% | 19.67% |
1 month | 20.94% | 8.42% |
6 months | -24.71% | 7.29% |
1 year | -32.66% | 12.71% |
5 years (annualized) | 11.50% | 10.75% |
10 years (annualized) | N/A | 9.87% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 | -1.30% | 9.45% | 3.80% | -11.46% | -15.64% | -20.78% | 18.28% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | -0.66 | ||||
^GSPC S&P 500 | 0.91 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Intellia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Intellia Therapeutics, Inc. was 86.90%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-86.9% | Sep 7, 2021 | 540 | Oct 27, 2023 | — | — | — |
-72.99% | Mar 12, 2018 | 507 | Mar 16, 2020 | 178 | Nov 25, 2020 | 685 |
-61.52% | Jun 1, 2016 | 251 | May 30, 2017 | 88 | Oct 3, 2017 | 339 |
-44.32% | Jan 20, 2021 | 33 | Mar 8, 2021 | 34 | Apr 26, 2021 | 67 |
-44.12% | Nov 1, 2017 | 31 | Dec 14, 2017 | 56 | Mar 8, 2018 | 87 |
Volatility Chart
The current Intellia Therapeutics, Inc. volatility is 27.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.